AMGN - Total Utang marang Modal Amgen Inc

The risk of losing patent protection for key drugs is creating pressure, as evidenced by the debt-to-equity ratio chart, where the current figure stands at 4.54. Amgen Inc. (AMGN) relies on its own biologics production paired with external distribution, while simultaneously accelerating the release of innovative obesity and cancer treatments to expand its market influence.

The total debt-to-equity ratio measures the proportion of borrowed funds relative to a company's equity. This ratio reflects the business's dependence on external financing and the stability of its balance sheet. By analyzing the debt-to-equity leverage chart, an investor assesses the risk of insolvency during periods of stagnation. For Amgen Inc. (AMGN), this indicator is critical, as the aggressive acquisition of startups requires significant borrowing. High leverage here serves as a tool to combat the expansion of biosimilars.